Atopic dermatitis (AD) is a chronic disease that affects an increasing number of children and adults. The skin is dry and ...

Sitryx advances development of PKM2 modulator SYX-5219 into atopic dermatitis patients following clinical evidence of immunomodulatory activity ...

Sanofi has announced that its amlitelimab has shown positive results in the treatment of patients 12 years and older with ...

Arcutis Biotherapeutics and Kowa Pharmaceuticals are cutting ties on their U.S. marketing partnership around Arcutis’ Zoryve ...

Sanofi has said it will press ahead with regulatory filings for atopic dermatitis (AD) candidate amlitelimab after reporting ...

Shares of Corvus Pharmaceuticals rose after its investigational drug soquelitinib showed positive results in an early-stage trial in atopic dermatitis patients. The stock surged 50% to $12.10 in ...

Amlitelimab is an investigational anti-OX40 ligand monoclonal antibody designed to normalize the overactive immune response in patients with atopic dermatitis.

Corvus Pharmaceuticals (NASDAQ:CRVS) shares surged 48% on Tuesday after the company released positive findings from a Phase 1 ...

A new study published in the Journal of the American Medical Association showed that asthma, allergic rhinitis, and atopic ...

If you’re a person of color, finding the right treatment for atopic dermatitis, a common form of eczema, can be challenging. Even though the disease is more prevalent in Black Americans than white ...

Sanofi has reported mixed phase 3 data on amlitelimab, further muddying the prospec | Sanofi has reported mixed phase 3 data ...